FindTrial
Sign In

Treatment of Bacterial Vaginosis in women with Mazoo

Management of Bacterial Vaginosis with Mazoo in Women of Reproductive Age Groups- An Observational Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/03/032337
Enrollment
30
Registered
2021-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N899- Noninflammatory disorder of vagina, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

Rajiv Gandhi University of Health Science Karnataka
Lead Sponsor
Dr Hafeeza
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All married women in the reproductive age group of 20 to 45 years Patients complaining of whitish to Yellow discharge per vagina

Exclusion criteria

Exclusion criteria: Patient presenting with blood stain discharge per vaginum Pregnant women Patients with STDs Patient with organic Pelvic Pathology Patient with associated diseases like DM HTN Liver and renal Diseases Patients with any malignancy

Design outcomes

Primary

MeasureTime frame
To prove the efficacy of Unani drug Mazoo in the treatment of bacterial VaginosisTimepoint: 3 weeks—

Secondary

MeasureTime frame
To Prove the efficacy of Mazoo in the management of Bacterial VaginosisTimepoint: 8 weeks—

Countries

India

Contacts

Public ContactDr Hafeeza

CCIM, India and Rajiv Gandhi University of Health Science, Karnataka

drhafeezamd@gmail.com9886466032

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026